System Organ Class
Preferred Term |
Placebo
(N=32) |
5mg CCX140-B
(N=63) |
10mg CCX140-B
(N=32) |
30mgPioglitazone
(N=32) |
Subjects reporting any adverse events—no. (%) |
6 (19.4) |
19 (30.2) |
6 (19.4) |
7 (22.6) |
Subjects with adverse events by system organ class with an incidence of ≥ 3% in any treatment group—no. (%) |
Gastrointestinal disorders |
2 (6.5) |
10 (15.9) |
1 (3.2) |
2 (6.5) |
Nausea |
0 (0.0) |
1 (1.6) |
1 (3.2) |
0 (0.0) |
Constipation |
0 (0.0) |
2 (3.2) |
0 (0.0) |
0 (0.0) |
Diarrhea |
1 (3.2) |
2 (3.2) |
0 (0.0) |
2 (6.5) |
Dry mouth |
1 (3.2) |
1 (1.6) |
0 (0.0) |
0 (0.0) |
Dyspepsia |
0 (0.0) |
2 (3.2) |
0 (0.0) |
0 (0.0) |
Flatulence |
0 (0.0) |
2 (3.2) |
0 (0.0) |
0 (0.0) |
Infections |
3 (9.7) |
3 (4.8) |
1 (3.2) |
1 (3.2) |
Nasopharyngitis |
2 (6.5) |
1 (1.6) |
1 (3.2) |
0 (0.0) |
Influenza |
0 (0.0) |
0 (0.0) |
0 (0.0) |
1 (3.2) |
Urinary tract infection |
1 (3.2) |
1 (1.6) |
0 (0.0) |
0 (0.0) |
Nervous system disorders |
2 (6.5) |
2 (3.2) |
1 (3.2) |
2 (6.5) |
Headache |
1 (3.2) |
0 (0.0) |
1 (3.2) |
1 (3.2) |
Dizziness |
1 (3.2) |
2 (3.2) |
0 (0.0) |
1 (3.2) |
Syncope |
1 (3.2) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
General disorders and administration site conditions |
1 (3.2) |
2 (3.2) |
1 (3.2) |
1 (3.2) |
Fatigue |
1 (3.2) |
1 (1.6) |
1 (3.2) |
0 (0.0) |
Edema peripheral |
0 (0.0) |
0 (0.0) |
0 (0.0) |
1 (3.2) |
Investigations |
2 (6.5) |
2 (3.2) |
0 (0.0) |
0 (0.0) |
Liver palpable subcostal |
1 (3.2) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
Occult blood positive |
1 (3.2) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
Musculoskeletal and connective tissue disorders |
0 (0.0) |
1 (1.6) |
1 (3.2) |
2 (6.5) |
Gouty arthritis |
0 (0.0) |
0 (0.0) |
1 (3.2) |
0 (0.0) |
Back pain |
0 (0.0) |
0 (0.0) |
0 (0.0) |
2 (6.5) |
Vascular disorders |
0 (0.0) |
4 (6.3) |
0 (0.0) |
0 (0.0) |
Hypertension |
0 (0.0) |
3 (4.8) |
0 (0.0) |
0 (0.0) |
Metabolism and nutrition disorders |
0 (0.0) |
2 (3.2) |
0 (0.0) |
1 (3.2) |
Hypoglycemia |
0 (0.0) |
0 (0.0) |
0 (0.0) |
1 (3.2) |
Skin and subcutaneous tissue disorders |
1 (3.2) |
1 (1.6) |
1 (3.2) |
0 (0.0) |
Pruritus |
0 (0.0) |
0 (0.0) |
1 (3.2) |
0 (0.0) |
Rash papular |
1 (3.2) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
